Coronary disease & ACSRandomised controlled trial
Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial
- Randomised controlled trial
- multicentre
- non-inferiority
- double-blind
- 13 cardiac surgery centres in China
Authors' conclusion
A three month DAPT strategy was non-inferior to the 12 month DAPT strategy in saphenous vein graft occlusion and was superior in reducing bleeding risk.
Study context
- Population
- Adults aged 18–80 years undergoing elective primary CABG with ≥1 saphenous vein graft2,290 in modified ITT set
- Participants
- 2,300 adults
- Comparison
- 3-month vs 12-month dual antiplatelet therapy (DAPT) after CABG
- Primary endpoint
- Saphenous vein graft occlusion (non-inferiority) and BARC type 2, 3 or 5 bleeding (superiority)
- Follow-up
- 1 year
Primary result
Saphenous vein graft occlusion
Absolute difference
−0.31%
95% CI −3.13% to 2.52%
P = 0.008 for non-inferiority
Events by treatment group
3-month DAPT vs 12-month DAPT
absolute difference −0.31% (95% CI −3.13% to 2.52%); P for non-inferiority = 0.008
As reported in the abstract
Secondary outcomes
| Outcome | 3-month DAPT | 12-month DAPT | absolute difference (95% CI) | |
|---|---|---|---|---|
| MACCE | 2.3% | 2.7% | −0.11% (−1.48% to 1.26%) | |
| −2−1012Difference (linear scale) |
Other secondary outcomes (graft failure, stenosis, occlusion)
- Similar between the two groups
Safety
| Outcome | 3-month DAPT | 12-month DAPT | absolute difference (95% CI) | P value | |
|---|---|---|---|---|---|
| BARC type 2, 3 or 5 bleeding (co-primary, superiority) · median follow-up 368 days (IQR 358-382) | 8.3% | 13.2% | −4.67% (−7.18% to −2.16%) | P < 0.001 | |
| −10−505Difference (linear scale) |
- Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding (co-primary, superiority) — NNT to prevent one bleeding event
- 21 (95% CI 13 to 46)
Original publication
Efficacy of dual antiplatelet therapy for three months versus 12 months after coronary artery bypass grafting: multicentre, double blinded, randomised controlled trial. BMJ. Published 12 May 2026. doi:10.1136/bmj-2025-088939
Summarised from the published abstract; every number is checked against it